Related Experiment Video
Updated: Sep 3, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
MASLD and MASH: Steatotic liver disease joins the deadly quartet
Risheng Xu1, Nicola Abate2, Rise Stribling3
1Assistant Professor-Hospitalist, Department of Medicine, Baylor College of Medicine, Houston, TX risheng.Xu@bcm.edu.
Abstract:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to insulin resistance and cardiometabolic disorders. This review synthesizes current information on the epidemiology, pathophysiology, and treatment of MASLD and its progressive form, metabolic dysfunction- associated steatohepatitis (MASH), underscoring how to integrate established metabolic care with emerging treatments to address the growing MASLD burden.
Related Concept Videos
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Hepatic Encephalopathy
Cirrhosis II: Pathophysiology
Cirrhosis I: Introduction
